WHO

LeafCann’s mission is to be a thought leading pioneer in the emerging new medicinal cannabis industry. With a philosophy of Patient before Profit, our goal is to provide patients and professionals with a safe, reliable and affordable natural medicine for chronic pain management. We have a world-class management team and leading international professionals on our advisory board who bring decades of combined experience working with and in regulated Medical Cannabis Schemes. Together they have put together LeafCann’s overall business strategy. 


Why

For decades the physical effects of chronic, life-threatening and terminal illnesses like cancer, MS and epilepsy have been treated with pharmaceutical drugs. However, anyone with first hand experience of caring for people with these conditions will know that the side effects of many pharmaceutical products used to manage pain, such as morphine or pethidine, have a significant negative impact for many users. Until now, non-toxic alternatives like medical cannabis have not been legally available in Australia. 


What

Many pharmaceutical products are prescribed as the best available, despite being not specifically fit for purpose. Now all that is changing. The passing of the Narcotic Drugs Amendment in February 2016 means that Australians affected by chronic pain will now have access to an effective natural and non-toxic alternative – medical cannabis. 


How

Results from countries that have already approved medical cannabis are outstanding. Now LeafCann is ready be one of this country’s first pioneers in the new medical cannabis industry. On a global stage, Australia has the opportunity to take a leading role in the development of medical cannabis through its reputation as an innovative country with a strong heritage in medical research, product development and farming/ cultivation. Perhaps the greatest positive for medical cannabis is the overwhelming approval by the Australian public (Roy Morgan, 2015). 

LC 361 2016_Web Design 1_graph74.jpg
LC 361 2016_Web Design 1_graph78.jpg